RI HIE first to exchange behavioral health data

CurrentCare, Rhode Island’s health information exchange, is the first to exchange behavioral health data electronically. The Providence Center and Gateway Healthcare were the first organizations to submit behavioral health and substance abuse treatment information, known as 42 CFR Part 2 data, into CurrentCare.

CurrentCare’s opt-in model requires informed patient consent before CurrentCare can collect information about a patient and share it with the patient’s authorized healthcare providers. For behavioral health patients, this enables medical and behavioral health providers to work more closely together to provide coordinated, patient-centered treatment, according to a release.

Dale K. Klatzker, PhD, president and CEO of The Providence Center, said, “By sharing health records with our primary care partners, our more than 500 clinical staff are able to give and get a full picture of an individual’s behavioral health and primary care needs wherever they are providing care. The EHR not only provides a full record of medications, diagnosis and treatment histories for people with complex needs, it acts as a voice for people who often have trouble accessing and receiving quality healthcare.”

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.